A PSA only recurrence (biochemical failure) post a primary treatment for prostate cancer is relatively common, approximately 30% of those treated! A biochemical failure is characterized a return of increasing PSA without any other evidence of cancer on a scan. Failure can happen immediately after primary treatment has been completed or many years after the [...]
To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]
Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer. For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time [...]
This study estimated and projected the number of years of potential life lost (YPLL) among men who die of prostate cancer(advanced prostate cancer) in the United States from 2004 through 2050 and compare the projections by race/ethnicity and age, accounting for demographic changes and population growth. The researchers applied the life expectancy method to estimate [...]
What is the primary treatment for men with advanced prostate cancer? We all know the answer, it is hormone therapy. Almost without exception, when we get diagnosed, we are put on to hormone therapy (ADT). ADT makes us feel terribly, it affects our stamina, our memory, our attention span, gives us hot flashes and weakens [...]